Reduction of migrainous headaches during the use of acenocoumarol.

Disappearance of migraine during the use of warfarin and of phenprocoumon has been described in sporadic case reports. Treatment with heparin has also been associated with a reduction of migranous headaches. Recently, the Netherlands Pharmacovigilance Foundation LAREB received a case report concerning the diminution of migrainous headaches associated with the use of the vitamin K antagonist, acenocoumarol.

Ciprofloxacin does not impair the elimination of diazepam in humans.

The pharmacokinetics of a single iv dose of 10 mg diazepam and the renal excretion of its metabolites resulting from N-demethylation and C-3-hydroxylation were investigated in 10 healthy volunteers when diazepam was administered alone and on day 3 of administration of the fluoroquinolone ciprofloxacin (500 mg twice per day). No significant changes in the diazepam half-life, its volume of distribution, the total body clearance, or the renal clearance were observed. In addition, the renal excretion of the metabolites desmethyldiazepam, 3-hydroxydiazepam (temazepam), and 3-hydroxydesmethyldiazepam (oxazepam) were not altered by ciprofloxacin co-medication.

Release and antimicrobial activity of silver sulphadiazine from different creams.

The release and antimicrobial activity of silver sulphadiazine from five different creams were studied: unguentum emulsificans aquosum, unguentum hydrophylicum non ionogenicum, paraffin cream (15 per cent), a homemade preparation and a commercially available preparation (Flamazine). A diffusion cell was used to measure the release and the agar well diffusion technique to determine the antibacterial activity of the silver sulphadiazine released. The paraffin cream (15 per cent) preparation had the highest release rate, followed by the homemade cream and the commercially available cream.